Monday, Tango Therapeutics, Inc. (TNGX) announced positive initial data from its ongoing Phase 1/2 study of vopimetostat in combination with Revolution Medicines' RAS(ON) inhibitors daraxonrasib or zoldonrasib.
During the study, patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal adenocarcinoma or PDAC were treated with a vopimetostat-based combination with either daraxonrasib or zoldonrasib.
The company said that 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieved an objective response. The combination achieved a 100% disease control rate in PDAC patients.
Meanwhile, in the vopimetostat plus zoldonrasib dose escalation arm, patients achieved 52% overall response rate and 74% 6-month progression-free survival rate.
Following these results, the company plans to finalize design of Phase 3 randomized-controlled trial of the combination approach in front-line pancreatic cancer in the second half of 2026.
During the same period, Tango plans to disclose vopimetostat lung cancer monotherapy data, release initial TNG456 glioblastoma data, present 2/3L PDAC vopimetostat + RAS(ON) inhibitors combination data, and initiate phase 1/2 vopimetostat + ERAS-0015 combination study.
In the pre-market hours, TNGX is surging 49.29 percent, to $30.15 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.